Phoenix Nest Secures $1.49 Million NIH Grant to Advance Gene Therapy Manufacturing for Sanfilippo Syndrome Type C
Key Insights
Phoenix Nest (search) received a $1.49 million NIH SBIR grant from NINDS to fund manufacturing of JLK-247, a gene therapy for MPS IIIC (Sanfilippo syndrome type C (search)).
The funding will support production of a 500-liter cGMP vector batch and analytical development ahead of a planned Phase I clinical trial.
MPS IIIC is an ultra-rare pediatric neurodegenerative disease with no approved therapies, caused by HGSNAT (search) enzyme deficiency leading to heparan sulfate accumulation.
Phoenix Nest (search), a Brooklyn, New York-based biotechnology company, has been awarded a $1.49 million Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) to advance manufacturing and analytical development of JLK-247, its investigational gene therapy for Mucopolysaccharidosis Type IIIC (search) (MPS IIIC), also known as Sanfilippo syndrome type C (search). The grant will fund production of a 500-liter current good manufacturing practice (cGMP) batch of the viral vector, positioning the program for a planned Phase I clinical trial.
The award represents a critical step toward first-in-human dosing for a disease that currently has no approved disease-modifying therapies. Phoenix Nest (search), led by principal investigator Srikanth Singamsetty, has reported a positive prior interaction with the FDA regarding its clinical development path, though no clinical efficacy or safety data have yet been generated for JLK-247.
The Unmet Need in MPS IIIC
MPS IIIC is caused by a deficiency of the enzyme heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT (search)), which leads to the pathological accumulation of heparan sulfate and progressive neurodegeneration in affected children. The disease is uniformly fatal, with death typically occurring by the mid-30s. Critically, because the deficient enzyme is membrane-bound within lysosomes, MPS IIIC is not amenable to conventional enzyme replacement therapy — a cornerstone of treatment for several other lysosomal storage disorders. This biological constraint leaves gene therapy as one of the few viable therapeutic modalities for addressing the underlying cause of the disease.
Phoenix Nest (search) describes JLK-247 as a candidate for the first indication-specific treatment for MPS IIIC. The company's approach aims to deliver a functional copy of the HGSNAT (search) gene to affected cells, potentially restoring enzymatic activity and halting or reversing the neurodegenerative process.
Grant Scope and Manufacturing Strategy
The NINDS SBIR award will support a comprehensive manufacturing readiness package, including vector scale-up, analytical assay qualification, and stability and sterility testing. Notably, most of the funded work will be executed through a contract development and manufacturing organization (CDMO) rather than in-house, a strategy that allows the small biotech to leverage specialized infrastructure and expertise for producing clinical-grade material.
The 500-liter cGMP batch represents a significant scale-up milestone, moving the program from research-grade production toward the quality and quantity standards required for human clinical trials. This manufacturing campaign is a prerequisite for filing an Investigational New Drug (IND) application with the FDA.
Broader Context and Significance
The grant reflects continued NINDS support for late-preclinical manufacturing readiness in rare pediatric neurodegenerative diseases, a funding category that has expanded as more small biotechnology companies advance viral vector programs toward IND filing. For the Sanfilippo syndrome community — patients, families, and clinicians who have long faced a complete absence of disease-modifying treatment options — the advancement of JLK-247 toward clinical testing offers a tangible step forward in addressing an ultra-rare disease with devastating consequences.